Kulika Weizman

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably. In fiscal 2025, which ended on September 30, 2025, the Siemens Group generated revenue of €78.9 billion and net income of €10.4 billion. As of September 30, 2025, the company employed around 318,000 people worldwide on the basis of continuing operations.

VenoStent is a venture backed, clinical stage medical device and tissue engineering company developing bioabsorbable wraps to transform outcomes in vascular surgery

Kolibri revolutionises the way we grow cells at scale using acoustic waves. Showing 100x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly.

Tierra Biosciences is a synthetic biology company that accelerates the pace of discovery and enables the next generation of bio-based materials. Tierra’s first product, the Tierra Protein Platform, couples high-throughput protein manufacturing with the simplicity of e-commerce to make ordering custom proteins easier than ever before. By lowering the traditional protein synthesis barrier, Tierra serves scientists looking to change the world with novel proteins. Led by a team of protein experts, this fast-growing company is transforming the way people discover, screen, and develop proteins for future bio-based products. For more information, visit tierrabiosciences.com.

Synvivia builds technology to control cell behavior.

NxLite (Formely 3E Nano) was founded in November 2015 by a group of experienced entrepreneurs with extensive solar energy and nano-technology backgrounds representing science, engineering, business development, commercialization, sales and finance. The company has developed and is commercializing high performance thermally and optically smart, nano-thin, Solar/Energy Control coatings. It has partnered with industry leading players to bring its product to market and is supported financially by Sustainable Development Technology Canada, Ontario Centres of Excellence and Bioindustrial Innovation Canada. At 3E Nano our goal is simple: manufacture a nano-technology coating that when deployed in the market will reduce greenhouse gases by 1 giga tonne per year by 2050.

Rhaeos is a VC backed, clinical stage medical device company developing FlowSense, a platform technology and a noninvasive wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. The company is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There is no technology available today that can easily assess CSF flow in shunts wirelessly, bedside, and without capital equipment until now with FlowSense. FlowSense, is a proprietary wireless, wearable, and noninvasive sensor that can be mounted on skin overlying the shunt to detect the presence and magnitude of CSF. Its miniaturized, thin construction is similar in size to a bandage, and it is composed primarily of soft, silicone rubber with no hard edges. Data is wirelessly transmitted to a custom designed mobile app. Rhaeos received FDA breakthrough designation for FlowSense, is NIH and NSF funded (>$7.5M), published clinical data in Science and Nature family journals, and is on track for initial market entry in 2024. To date, the company has brought in >$19M in dilutive and non-dilutive financing. Follow on products for other chronic conditions are currently in development.

Were developing technologies to replicate cancer patients disease ex-vivo to rapidly and accurately test a broad range of treatments simultaneously to help oncologists provide the most suitable treatment for each patient and pharmaceutical companies develop transformational therapies.

To address the exploding demand for efficacious mental healthcare globally, Mobio Interactive has developed and commercialised an AI-powered digital theragnostic platform that delivers clinically validated psychotherapy programmes personalised to every patient using digital biomarkers that quantify human brain states without relying on a wearable.

Cytonus is reinventing drug-discovery and drug-delivery by questioning the principled approaches of pharmacodynamics (physiological effects of drugs) that has failed patients since the start of medicine. With a revolutionary platform technology called the Cargocyte, we believe the days of flooding the body with medicines with a hope and prayer to effect disease is not only antiquated, it is scientifically flawed. With a combination of precision drug delivery and in-vivo drug production the Cargocyte platform enables science and medicines to new level of effectiveness without compromising safety for patients.

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably. In fiscal 2025, which ended on September 30, 2025, the Siemens Group generated revenue of €78.9 billion and net income of €10.4 billion. As of September 30, 2025, the company employed around 318,000 people worldwide on the basis of continuing operations.

Creative Ventures is a deep tech venture firm investing in early-stage companies solving humanitys most critical crises. Led by a team of world-class experts, our deep tech acumen is informed by rigorous research, unmatched market understanding, and the dedication to lead our companies to success. Todays problems cant be solved by yesterdays solutions. Lets get Creative.

VenoStent is a venture backed, clinical stage medical device and tissue engineering company developing bioabsorbable wraps to transform outcomes in vascular surgery

Kolibri revolutionises the way we grow cells at scale using acoustic waves. Showing 100x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly.

Tierra Biosciences is a synthetic biology company that accelerates the pace of discovery and enables the next generation of bio-based materials. Tierra’s first product, the Tierra Protein Platform, couples high-throughput protein manufacturing with the simplicity of e-commerce to make ordering custom proteins easier than ever before. By lowering the traditional protein synthesis barrier, Tierra serves scientists looking to change the world with novel proteins. Led by a team of protein experts, this fast-growing company is transforming the way people discover, screen, and develop proteins for future bio-based products. For more information, visit tierrabiosciences.com.